Michael Davidson Sells 443,707 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 443,707 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. This trade represents a 71.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

NewAmsterdam Pharma Stock Down 7.4%

Shares of NAMS opened at $30.41 on Wednesday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company’s fifty day moving average is $33.88 and its two-hundred day moving average is $33.15. The firm has a market cap of $3.50 billion, a PE ratio of -17.58 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of large investors have recently added to or reduced their stakes in NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in NewAmsterdam Pharma in the 1st quarter worth $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock worth $5,898,000 after acquiring an additional 34,563 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of NewAmsterdam Pharma in the second quarter worth about $212,000. Bank of New York Mellon Corp acquired a new position in shares of NewAmsterdam Pharma in the second quarter worth about $6,392,000. Finally, Geode Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after purchasing an additional 13,629 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on NAMS shares. The Goldman Sachs Group increased their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Guggenheim upped their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.10.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.